Atopic dermatitis is a common chronic recurrent inflammatory skin disease. Previous therapeutic drugs include topical glucocorticoids, topical calcineurin inhibitors, oral antihistamines, systemic immunosuppressants and glucocorticoids, etc. In recent years, biologics and a variety of small-molecule drugs have been approved for the treatment of atopic dermatitis. Based on recent research progress, Chinese and international guidelines or consensus, and experts' clinical experience, China Dermatologist Association, Chinese Society of Dermatology, Dermatology Branch of China International Exchange and Promotive Association for Medical and Health Care, State Key Laboratory of Complex Severe and Rare Diseases, and National Clinical Research Center for Dermatologic and Immunologic Diseases convened experts to develop this consensus on strategies for the clinical application of therapeutic drugs for atopic dermatitis, monitoring and management of adverse drug reactions, and drug management in special populations, aiming to provide a reference for the application and management of therapeutic drugs for atopic dermatitis.

Dermatitis, atopic; Medication therapy management; Biological agents; Molecular targeted therapy; Drug toxicity; Special population; Expert consensus